Table 2 Reports of SETDB2 and its role in different cell types
From: Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
| Cell type(s) | Reported aberration of SETDB2 | Regulatory role of SETDB2 | Downstream target genes | Biological effects of SETDB2 activity | Reference |
|---|---|---|---|---|---|
| Acute lymphoblastic leukaemia | Upregulation | Inhibition | CDKN2C | Hyperproliferation | [87] |
| Gastric cancer | Upregulation | Inhibition | WWOX and CADM1 | Apoptotic inhibition/may promote metastasis | [92] |
| Colorectal and gastric cancer | Frameshift mutation | – | – | Increased microsatellite instability | [94] |
| Renal cell carcinoma | Downregulation | – | – | Promotes metastasis | [91] |
| Breast cancer | Homozygous deletion | – | – | Associated with greater survival of breast cancer patients | [90] |
| Chronic lymphocytic leukaemia (CLL) | 1 Mb deletion | – | – | Associated with CLL progression | [93] |
| Melanoma, lung adenocarcinoma, colorectal carcinoma | Upregulation | Inhibition | – | Higher expression of SETDB2 associated with adaptive resistance | [15] |